News and Updates

The Pharmacy Benefits and Advisory Committee (PBAC), consisting of clinical subject matter experts within Michigan Medicine and the University of Michigan, meets regularly to review and approve changes to the Prescription Drug Plan formulary. This page provides updates regarding the plan’s formulary, changes to coverage policies, and other relevant Prescription Drug Plan news for plan members. Check this page frequently for the latest information.

June 2020

Formulary Updates

Effective June 1, 2020, the following changes will be made to the Prescription Drug Plan’s formulary. These changes will be reflected in the plan’s next bi-monthly print formulary. Review the formulary.

 New Drug Products Added to Formulary

  • Lemborexant (Dayvigo) – Tier 3, ST, QL
  • Osilodrostat (Isturisa) – Tier 2, Specialty, PA, QL
  • Pemigatinib (Pemazyre) – Tier 2, Specialty, PA, QL
  • Tucatinib (Tukysa) – Tier 2, Specialty, PA, QL
  • Icosapent Ethyl (Vascepa) – Tier 3, PA, QL

New Generics Added to Formulary

  • Insulin Lispro Junior Kwikpen (Humalog Junior Kwikpen)
  • Insulin Lispro Mix Protamine Mix Kwikpen (Humalog Mix 75-25 Kwikpen)

Look for New Drug Plan ID Cards

New prescription drug plan ID cards from Magellan Rx Management will mail to plan members in June. Magellan Rx will be the plan's new pharmacy benefit manager effective July 1, 2020.

Is Your Address up to Date With the University?

To help ensure you receive your new cards, please make sure your home mailing address is up to date with the university. To review your address, go to Employee Self Service on Wolverine Access, select Campus Personal Information, and then select Addresses. Please update your "Current Local" address before May 29, 2020.

Three Medications Now Available Over-the-Counter

Effective June 1, 2020, three medications will no longer be covered by the plan due to recent over-the-counter (OTC) availability: diclofenac (Voltaren) 1% gel, olopatadine (Pataday) 1% drops, and olopatadine 2% drops. Brand and generic versions of these products will soon be available without the need for a prescription at most retail pharmacies.

For more information, please refer to the FDA announcement, FDA Approves Three Drugs for Nonprescription Use Through Rx-to-OTC Switch Process.

May 2020

Effective May 1, 2020, the following changes will be made to the Prescription Drug Plan’s formulary. These changes will be reflected in the plan’s next bi-monthly print formulary. Review the formulary.

 New Drug Products Added to Formulary

  • Peanut Allergen Powder-dnfp (Palforzia) – Tier 2, Specialty, PA, QL
  • Rimegepant (Nurtec ODT) – Tier 3, Specialty, PA, QL
  • Bempedoic Acid (Nexletol) – Tier 3, PA, QL
  • Cenobamate (Xcopri) – Tier 3, ST, QL 

New Generics Added to Formulary

  • Teriparatide (Forteo)
  • Everolimus (Zortress)
  • Pyrimethamine (Daraprim)
  • Ketorolac Tromethamine Nasal Spray (Sprix)
  • Moxifloxacin Eye Drops (Moxeza)

April 2020

Advance Refill Override Extended through May 19

The emergency override announced in March that allows early refills for up to 90 days worth of supply during the coronavirus pandemic is extended through 11:59 p.m. (Eastern Time) on May 19, 2020. Governor Gretchen Whitmer has signed an extension to an existing Executive Order 2020-56, which increases the public's access to prescriptions. The limit for no prescription refills before 75% use (26 days for a 34-day supply or 68 days for a 90-day supply) has been lifted.

March 2020

Advance Refills Available

Effective March 16, 2020, the U-M Benefits Office implemented a refill override to ensure that Prescription Drug Plan members have access to their prescription maintenance medication effective through April 23, 2020. Plan members may get up to a 90-day supply of maintenance medication in advance of the usual refill schedule. Typically members must wait until 75 percent of the current fill has been used before requesting a refill. The limit for no prescription refills before 75% use (26 days for a 34-day supply or 68 days for a 90-day supply) has been lifted.

February 2020

Effective February 1, 2020, the following changes will be made to the Prescription Drug Plan’s formulary. These changes will be reflected in the plan’s next bi-monthly print formulary. Review the formulary.

New Drug Products Added to Formulary

  • Testosterone Undecanoate (Jatenzo) – Tier 3, PA, QL
  • Voxelotor (Oxbryta) – Tier 2, Specialty, PA, QL
  • Zanubrutinib (Brukinsa) – Tier 3, Specialty, PA, QL
  • Benralizumab (Fasenra) – Tier 3, Specialty, QL

New Generics Added to Formulary

  • Insulin Aspart (Novolog, Novolog Flexpen)
  • Eluryng (Nuvaring)
  • Budesonide Formoterol (Symbicort)
  • Everolimus (Afinitor)
  • Mesalamine ER (Apriso)
  • Deferasirox (Jadenu)
  • Travoprost (Travatan Z)
  • Sulconazole Nitrate 1% (Exelderm)

November 2019

Effective November 1, 2019, the following changes will be made to the Prescription Drug Plan’s formulary. These changes will be reflected in the plan’s next bi-monthly print formulary. Review the formulary.

New Drug Products Added to Formulary

  • Semaglutide (Rybelsus) – Tier 3, PA, QL
  • Pitolisant (Wakix) – Tier 2, Specialty, PA, QL
  • Istradefylline (Nourianz) – Tier 3, PA, QL
  • Lamivudine/Tenofovir (Temixys) – Tier 3, Specialty, QL
  • Glucagon (Gvoke Hypopen, PFS) – Tier 2, QL

New Generics Added to Formulary

Nitisinone (Generic for Orfadin)

October 2019

Effective October 1, 2019, the following changes will be made to the Prescription Drug Plan’s formulary. These changes will be reflected in the plan’s next bi-monthly print formulary. Review the formulary.

New Drug Products Added to Formulary

  • Upadacitinib (Rinvoq) – Specialty, Tier 2, PA, QL
  • Entrectinib (Rozlytrek) – Specialty, Tier 2, PA, QL
  • Fedratinib (Inrebic) – Specialty, Tier 3, PA, QL
  • Pexidartinib (Turalio) – Specialty, Tier 2, PA, QL
  • Tegaserod (Zelnorm) – Tier 3, PA, QL
  • Lefamulin (Xenleta) –Tier 3, PA, QL
  • C1 esterase inhibitor (Ruconest) – Specialty, Tier 2, PA

New Generics Added to Formulary

  • Posaconazole (Generic for Noxafil)
  • Triamterene (Generic for Dyrenium)

September 2019

Effective September 1, 2019, the following changes will be made to the Prescription Drug Plan’s formulary. These changes will be reflected in the plan’s next bi-monthly print formulary. Review the formulary.

New Drug Products Added to Formulary

  • Bremelanotide (Vyleesi) – Tier 3, PA, QL
  • Selinexor (Xpovio) – Tier 2, Specialty, PA, QL
  • Darolutamide (Nubeqa) – Tier 3, Specialty, PA, QL
  • Glucagon Nasal Powder (Baqsimi) – Tier 2, QL

New Generics Added to Formulary

  • Pregabalin (Generic for Lyrica)
  • Ramelteon (Generic for Rozerem)

        .